Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HB-1614
- Development stage
- Unknown
- Lead developer
- Halo Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HB-1614 is a proprietary, oral formulation of 4-methylumbelliferone (4-MU) developed by Halo Biosciences for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). The drug is designed to inhibit hyaluronan synthesis, a key driver of extracellular matrix remodeling involved in inflammation and fibrosis. By targeting this pathway, HB-1614 aims to provide a novel, disease-modifying approach for PH-ILD and potentially other fibrotic conditions. Clinical studies have shown that HB-1614 may improve exercise capacity in adults with PH-ILD[1][6].
- Other names
- 4-methylumbelliferone4-MU
02
Targets
HAS1 (Hyaluronan synthase 2)
Beyond the preview
Go deeper on HB-1614.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HB-1614.